Eli Lilly (LLY) CEO David Ricks awarded 38,913.584 shares

Filing Impact

(Very High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Ricks David A reported acquisition or exercise transactions in this Form 4 filing.

Eli Lilly & Co President, Chair, CEO and director David A. Ricks received a grant of 38,913.584 shares of common stock on February 9, 2026 at $1,044.67 per share. Following this award, he directly held 571,715.097 common shares.

He also reported indirect holdings through several vehicles, including the David A. Ricks 2025 GRAT, the David A. Ricks 2022 GRAT, a trust, the David A. Ricks SLAT, and a 401(k) account, while disclaiming beneficial ownership except to the extent of his pecuniary interest.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Ricks David A

Role President, Chair, and CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	38,913.584	$1,044.67	$40.65M
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 571,715.097 shares (Direct); Common Stock — 6,685 shares (Indirect, By David A. Ricks 2025 GRAT)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

02/11/2026 - 04:23 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ricks David A

(Last)

(First)

(Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS

46285

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President, Chair, and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/09/2026		A		38,913.584	A	$1,044.67	571,715.097	D
Common Stock								6,685	I⁽¹⁾	By David A. Ricks 2025 GRAT
Common Stock								54,117	I	By David A. Ricks 2022 GRAT
Common Stock								300	I⁽¹⁾	By Trust
Common Stock								68,656	I⁽¹⁾	By David A. Ricks SLAT
Common Stock								7,307.91	I	401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

Remarks:

	/s/ Jonathan Groff for David A. Ricks, pursuant to authorization on file	02/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Eli Lilly (LLY) report for David A. Ricks?

Eli Lilly reported that David A. Ricks received a grant of 38,913.584 shares of common stock on February 9, 2026. The Form 4 classifies this as an acquisition via grant or award, not an open-market purchase or sale, reflecting executive compensation in stock.

At what price were David A. Ricks’s Eli Lilly shares granted on February 9, 2026?

The 38,913.584 Eli Lilly common shares granted to David A. Ricks were valued at $1,044.67 per share. This price is reported in the Form 4 and is used to indicate the transaction value for this equity award to the company’s President, Chair, and CEO.

How many Eli Lilly shares does David A. Ricks directly own after this Form 4 transaction?

After the February 9, 2026 grant, David A. Ricks directly owns 571,715.097 Eli Lilly common shares. This total reflects his direct holdings only, separate from additional indirect positions held through trusts, GRATs, a SLAT, and a 401(k) plan reported in the filing.

What indirect Eli Lilly shareholdings associated with David A. Ricks are disclosed?

The filing shows indirect Eli Lilly holdings through the David A. Ricks 2025 GRAT, the David A. Ricks 2022 GRAT, a trust, the David A. Ricks SLAT, and a 401(k). The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest in them.

Does the Eli Lilly Form 4 indicate that David A. Ricks sold any shares?

No sales are reported; the coded transaction is an acquisition labeled as a grant, award, or other acquisition. The primary entry is a non-derivative stock grant, and the remaining line items update indirect holdings, with no disposition or sale transactions indicated in the disclosed table.